SUMMARY A method is described for the measurement of amiodarone and desethylamiodarone in small tissue samples. With the exception of fat, for which lipase is used, the tissues are digested with a proteolytic enzyme. After the addition of an internal standard the analytes are extracted from the homogeneous digest into an organic solvent and measured by high-performance liquid chromatography (HPLC) with UV detection at 240 nm. The method shows good reproducibility using tissue samples as small as 20 mg and suggests extensive accumulation of both compounds in some tissues, with particularly high concentrations in tissues associated with adverse effects of the drug.
Amiodarone is a class III antiarrhythmic agent' and in humans treated chronically with the drug the formation of a major metabolite, desethylamiodarone, has been demonstrated. 2 The development of an HPLC assay for the measurement of amiodarone in plasma3 has shown that the drug has an exceptionally long terminal half-life of elimination, (of the order of 50 days)4 and a very large volume of distribution (approximately 5000 l).5 Data on the tissue distribution of this drug are sparse, being confined to preliminary studies using radiolabelled drug6 and a study in rat tissue after single, intravenous, dosage in which few details of tissue preparation prior to HPLC analysis are given.7
In an effort to characterise the tissue distribution of the drug and its desethyl metabolite we have developed a method for their measurement in small (20-100 mg) (Applied Chromatography Systems, Model 750/11) and integration of peak areas was performed using a Hewlett-Packard 3352 data system. The mobile phase consisted of methanol: 2,2,4-trimethyl pentane: methyl tert-butyl ether (80:10:10) containing 6 mmol/I potassium bromide and was delivered at a flow-rate of 2.0 mlmin. For the analysis of rabbit tissue digest a mobile phase consisting of methanol: diethyl ether (85:15) containing perchloric acid (0-02% vol/vol) was used to facilitate the separation of the analytes from endogenous material.
The chromatography of an extract from a heparinised human plasma standard containing amiodarone, desethylamiodarone, L8040 and fenethazine on this system is illustrated in Fig. 2 Standard solutions containing amiodarone and desethylamiodarone at concentrations of 1-0, 2.0 and 3-0 mg/l were prepared in analyte-free human plasma, analyte-free pig myocardium digest and analyte-free human fat digest. A linear calibration graph with zero intercept and identical slope was obtained for amiodarone on the analysis of each set of standards. The extraction of desethylamiodarone was found to be 20% less from fat digest standards with respect of both plasma and heart digest standards. However, the tenfold dilution of fat digest in analyte-free human plasma, used in routine application of this method, eliminated this difference. The absolute recovery of amiodarone from plasma under these conditions was 98-6% + 3*3 (SD).
Results from diluted heart and fat digest standards were found to be directly comparable with plasma standards. Plasma standards of 0-5, 1-0, 2.0 and 3-0 mg/l were routinely used for the measurement of concentrations of amiodarone and desethylamiodarone from all diluted tissue digests.
Results
A chromatogram obtained on analysis of an extract of human myocardium digest containing neither amiodarone nor desethylamiodarone is shown in Fig. 2(b The results of the intra-assay reproducibility study for human heart and fat samples are summarised in Table 1 . The limit of sensitivity for the measurement of both compounds was 0*1 mg/kg wet weight using a 100 mg tissue sample.
Neither incubating at 500 for 16 h nor addition of enzyme solution affected the stability of amiodarone or desethylamiodarone in tissue digest spiked with these compounds.
This methodology has been applied successfully to the measurement of amiodarone and its desethyl metabolite in a wide variety of tissue samples from both humans and rabbits. Table 2 shows the concentration of the two compounds in post-mortem samples collected from three cases in which the patients died whilst receiving amiodarone therapy. JT A 67-year-old man, received amiodarone 400 mg daily for 6 months.
WH A 60-year-old man, received, on average, amiodarone 600 mg daily for 40 days. FB A 52-year-old man, received amiodarone 200 mg daily for 10 months. Similar results were obtained from biopsy samples collected at the time of operation from two patients receiving amiodarone chronically (Table 3) . JA A 33-year-old woman, received amiodarone for 4-5 yr, 800 mg daily for 5 months before operation. JG A 60-year-old man, received amiodarone 600 mg daily for 33 days. Finally, the compounds were measured in tissue samples collected at post-mortem from rabbits which had received 40 mg/kg/day amiodarone, peritoneally, for four weeks; the results are shown in Tissue concentration = mg/kg wet weight. These preliminary findings suggest an appreciable accumulation of both amiodarone and desethylamiodarone in some tissues, with fat forming a potentially large tissue reservoir of the drug. Of note is the fact that the ratio of amiodarone to desethlylamiodarone is lower in tissue than blood, with the exception of fat, this latter observation probably reflecting the greater lipid solubility of the parent compound. In addition, it may be significant that the concentration of both compounds is high in the liver and the lung, tissues associated with amiodarone-induced adverse effects; raised serum asparate aminotransferase activities, related to high concentrations of amiodarone and desethylamiodarone have been noted in some patients and the drug has been implicated in the development of pulmonary interstitial changes." The clinical significance of these findings is under active consideration and will be presented elsewhere (Adams, Storey, Holt, Campbell, in preparation 
